Market Place
Sourcing Support
Elevar Announces FDA Acceptance Of Rivoceranib For HCC Treatment
21 Oct 2024 //
GLOBENEWSWIRE
Elevar Resubmits NDA For Camrelizumab Plus Rivoceranib In HCC
23 Sep 2024 //
GLOBENEWSWIRE
Elevar Presents Rivoceranib Plus Camrelizumab Data At ESMO 2024
12 Sep 2024 //
GLOBENEWSWIRE
Elevar Therapeutics Gets EU Orphan Drug Designation For HCC Therapy
01 Aug 2024 //
GLOBENEWSWIRE
Elevar And Hengrui Plan Quick Refile After FDA Rejects Cancer Combo
10 Jul 2024 //
FIERCE PHARMA
Elevar Plans NDA Resubmission For Hepatocellular Carcinoma Treatment
09 Jul 2024 //
GLOBENEWSWIRE
Elevar Therapeutics Median OS 23.8 Mos In 1L Unresectable HCC
30 May 2024 //
GLOBENEWSWIRE
FDA rejects Elevar, Hengrui`s PD-1 combo
18 May 2024 //
FIERCE PGARMA
Elevar Therapeutics To Present Two Posters From Phase 3 CARES-310 Study
18 Jan 2024 //
GLOBENEWSWIRE
Elevar Therapeutics Names Brian Cunningham Vice President of Sales
23 Oct 2023 //
GLOBENEWSWIRE
Jiangsu Hengrui and Elevar Therapeutics Announce Agreement for Camrelizumab
17 Oct 2023 //
GLOBENEWSWIRE
Hengrui, Elevar strike $600M marketing deal for liver cancer med
17 Oct 2023 //
FIERCE PHARMA
Elevar Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference
21 Sep 2023 //
GLOBENEWSWIRE
Elevar Therapeutics Joins Benefactors Council of Blue Faery
19 Sep 2023 //
GLOBENEWSWIRE
Elevar Names Dr. Chris Galloway Vice President of Clinical Development
15 Aug 2023 //
GLOBENEWSWIRE
Elevar to Host August 10 Virtual KOL Event on Phase 3 Study of Rivoceranib
03 Aug 2023 //
GLOBENEWSWIRE
Elevar Announces Publication of Phase 3 CARES 310 Study Results in The Lancet
24 Jul 2023 //
GLOBENEWSWIRE
Elevar Announces Acceptance for Filing of NDA for Rivoceranib with Camrelizumab
17 Jul 2023 //
GLOBENEWSWIRE
Elevar Therapeutics to Participate in ASCO 2023 and BIO 2023
01 Jun 2023 //
GLOBENEWSWIRE
Elevar Submits NDA to FDA for Combination of Rivoceranib and Camrelizumab
17 May 2023 //
GLOBENEWSWIRE
Elevar Therapeutics Presents AACR 2023 Poster Demonstrating Rivoceranib
18 Apr 2023 //
GLOBENEWSWIRE
Elevar to Present Poster at AACR Demonstrating Rivoceranib as Poten for VEGFR-2
16 Mar 2023 //
GLOBENEWSWIRE
Elevar Therapeutics Debuts New Corporate Headquarters in Fort Lee, New Jersey
07 Mar 2023 //
GLOBENEWSWIRE
Elevar Announces Positive Pre-NDA Meeting for Rivoceranib Camrelizumab
11 Oct 2022 //
GLOBENEWSWIRE
Elevar Announces Camrelizumab Plus Rivoceranib Significantly Prolonged
07 Sep 2022 //
GLOBENEWSWIRE
Elevar Announces Data From PIII Study of Rivoceranib will be Presentated at ESMO
25 Aug 2022 //
GLOBENEWSWIRE
Elevar Therapeutics Names Wade Smith Chief Financial Officer
22 Aug 2022 //
GLOBENEWSWIRE
Elevar Tx Names Dr. Jan M. Van Tornout CMO, Dr. Gordon Schooley CRO
28 Jun 2022 //
GLOBENEWSWIRE
Elevar Therapeutics Shares Results of PII Rivoceranib Trial
06 Jun 2022 //
GLOBENEWSWIRE
Elevar Therapeutics Adds Drs. Honghui Zhou and David Lilienfeld as VPs
02 Jun 2022 //
GLOBENEWSWIRE
Elevar Tx Announces Rivoceranib Demonstrated Clinical Effectiveness in r/m ACC
26 May 2022 //
GLOBENEWSWIRE
Elevar Therapeutics Names Paul Friel CCO, Michael Palucki VP of Manufacturing
23 May 2022 //
GLOBENEWSWIRE
Elevar Therapeutics Announces New Appointments to its Board of Directors
26 Oct 2021 //
PRNEWSWIRE
Elevar Therapeutics Announce New Data Highlighting Patient Burden
18 May 2021 //
PRNEWSWIRE
Elevar Therapeutics Announce New Data Highlighting Patient Burden
18 May 2021 //
PRNEWSWIRE
Elevar Therapeutics Inc. Announces Licensing Agreement with Inceptua Group
28 Dec 2020 //
INCEPTUA
Elevar Therapeutics Inc. Announces Licensing Agreement with Inceptua Group
28 Dec 2020 //
INCEPTUA
Elevar & Tanner Pharma Group Announce Launch of Global Named Patient Program
01 Dec 2020 //
PRNEWSWIRE
Elevar Therapeutics Appoints Gus Aromin as Vice President of Regulatory Affairs
30 Nov 2020 //
PRNEWSWIRE
Elevar Therapeutics & Taiba Middle East Partner to Commercialize Apealea®
05 Oct 2020 //
PRNEWSWIRE
Adding Elevar`s EGFR drug to Iressa boosts survival in early lung cancer
21 Sep 2020 //
FIERCE BIOTECH
Elevar & Tanner Pharma Group Announce Global Named Patient Program Apealea®
27 Jul 2020 //
PRNEWSWIRE
Oasmia receives upfront payment of 20 MUSD from Elevar
21 Apr 2020 //
PRESS RELEASE
